What Is Hydroxydaunorubicin?

Daunorubicin for injection contains 20mg daunorubicin hydrochloride (potency) and 100mg D-mannitol. It is used for acute myeloid leukemia, acute lymphocytic leukemia and other tumors.

Daunorubicin for injection

This entry lacks an information bar and an overview map . Supplementing related content makes the entry more complete and can be upgraded quickly. Come on!

For injection

The main ingredient of this product is daunorubicin hydrochloride. The chemical name is 5,10-tetrabenzoquinone, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-aL-lai Sulfuryl) -oxy] -7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy hydrochloride. This product is red

Common name: Daunorubicin hydrochloride for injection Name used: Daunorubicin Hydrochloride for Injection English name: Zhu she yong Yan suan Rou hong mei su

Daunorubicin is a cycle non-specific antitumor drug. Animal experiments have shown that it has a life-prolonging effect on mouse L1210 leukemia, and it also shows certain resistance to carbamic acid, 6-mercaptopurine, and 5-fluorouracil. Efficacy. In addition, it has a long-lasting effect on Yoshida sarcoma rats, and is resistant to cyclophosphamide, triethylenethiophosphoramid, 6-mercaptopurine, 5-chlorouracil, mitomycin C, and tryptomycin A3. The cell line also showed some efficacy. The mechanism of daunorubicin lies in the cell's nucleic acid synthesis process, which can directly bind to DNA and hinder DNA synthesis and DNA-dependent RNA synthesis reactions.

This product is for intravenous injection or instillation. Just before use, 10 ml of physiological saline for injection is dissolved. The dosage for adults in a course of treatment is 0.4-1.0 mg / kg (body weight), and for children is 1.0 mg / kg, once a day for a total of 3-5 times, administered continuously or every other day. Repeat after one week of withdrawal. The total dose does not exceed 600 mg / square.

1. Myocardial injury, abnormal electrocardiogram, tachycardia, etc. When the total dose exceeds 25mg / kg, it can cause severe myocardial damage.
2. Inhibit bone marrow hematopoiesis; anemia, decreased granulocytes, and bleeding.
3. Allergies; fever, rash.
4. Liver damage. GOP, GPT, AI-P increased, jaundice.
5. Kidney damage. BUN increased, proteinuria.
6. Digestive organs. Ulcerative stomatitis, loss of appetite, nausea, vomiting, etc.
7. Hair loss.
8. Mental symptoms such as burnout, headache, dizziness.
9. Chills, difficulty breathing, etc.

1. Patients with heart disease and patients with a history of heart disease.
2. Patients with a history of severe allergies to this drug.
3. Pregnant and lactating women.

1. It must be used under the guidance of a physician. Blood medication, liver function, and ECG changes should be closely monitored during medication, and dose should be reduced or discontinued when abnormal.
2. This medicine can only be used for intravenous injection.
3. Pay attention to the site and method when intravenous injection, as slow as possible to prevent causing vascular pain, phlebitis and thrombosis.
4. Intravenous injection should be injected to prevent the drug solution from leaking out of the blood vessel, so as not to cause tissue damage and necrosis.

Drugs for pregnant and lactating women 1. Teratogenic reports have been reported in animal experiments (mouse). Pregnant women or women who may become pregnant are contraindicated.
2. Avoid administering medication to lactating women. Breastfeeding should be discontinued when medication is necessary (the safety of medication during lactation has not been determined).

Medication for children 1. When using medication for children, special attention should be paid to the occurrence of adverse reactions, and it should be used with caution. 2. For children and patients of reproductive age, if the drug must be administered, the effect on the gonads should be considered.

Medication for elderly patients This drug is mainly metabolized by the liver. Physiological functions such as liver function in elderly patients are reduced. Use with caution.

Can be combined with prednisone, cytarabine or vinblastine to increase its efficacy.